Article
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)
array:24 [ "pii" => "S2253808915000932" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.002" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "695" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "copyrightAnyo" => "2015" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:398-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 42 "formatos" => array:2 [ "HTML" => 25 "PDF" => 17 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S2253654X15000530" "issn" => "2253654X" "doi" => "10.1016/j.remn.2015.04.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "695" "copyright" => "Elsevier España, S.L.U. y SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:398-9" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 636 "formatos" => array:3 [ "EPUB" => 13 "HTML" => 392 "PDF" => 231 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Imágenes de interés</span>" "titulo" => "Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con <span class="elsevierStyleSup">11</span>C-metionina" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "398" "paginaFinal" => "399" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Diagnosed recurrent glioma and antiangiogenic treatment response by <span class="elsevierStyleSup">11</span>C-Methionine PET" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2374 "Ancho" => 3250 "Tamanyo" => 548019 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">A: estudio tras tratamiento Stupp. Imagen RM secuencia T1. Imagen RM secuencia Flair, Imagen de fusión PET/RM por software (SPM8). Imagen PET con 11C-metionina.</p> <p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">La RM pone de manifiesto una lesión redondeada en la rodilla del cuerpo calloso, de 22<span class="elsevierStyleHsp" style=""></span>x<span class="elsevierStyleHsp" style=""></span>18, con edema vasogénico frontal anterior contiguo bilateral, que sugiere recidiva local.</p> <p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">El estudio PET con 11C-metionina muestra un comportamiento hipermetabólico de esta lesión (relación SUV lesión/fondo 5,6/1,6) que confirma la recidiva tumoral. La cuantificación se realiza mediante la relación entre el grado de captación de la lesión (SUV máximo) y el fondo de sustancia gris del lóbulo contralateral sano (SUV medio).</p> <p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">Figura 1-B: estudio tras tratamiento con bevacizumab. Imagen RM secuencia T1. Imagen RM secuencia Flair, Imagen de fusión PET/RM por software (SPM8). Imagen PET con 11C-metionina.</p> <p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">La RM pone de manifiesto un aumento del tamaño de la lesión localizada en la rodilla del cuerpo calloso (27<span class="elsevierStyleHsp" style=""></span>x<span class="elsevierStyleHsp" style=""></span>24) con similar extensión del edema perilesional.</p> <p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">El estudio PET con 11C-metionina muestra la resolución de la actividad metabólica en la lesión, confirmando la respuesta al tratamiento antiangiogénico, por lo que se continúa la terapia, sin signos posteriores que sugieran recidiva.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J.R. García, M. Baquero, P. Bassa, M. Soler, M. Moragas, E. Riera" "autores" => array:6 [ 0 => array:2 [ "nombre" => "J.R." "apellidos" => "García" ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baquero" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Bassa" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Soler" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Moragas" ] 5 => array:2 [ "nombre" => "E." "apellidos" => "Riera" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S2253808915000932" "doi" => "10.1016/j.remnie.2015.09.002" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000932?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X15000530?idApp=UINPBA00004N" "url" => "/2253654X/0000003400000006/v1_201510300043/S2253654X15000530/v1_201510300043/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S2253808915000944" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.003" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "721" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:400-11" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 88 "formatos" => array:2 [ "HTML" => 60 "PDF" => 28 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Special collaboration</span>" "titulo" => "XXXV SEMNIM Congress. Highlights" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "400" "paginaFinal" => "411" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "XXXV Congreso de la SEMNIM. Conferencia Resumen" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0035" "etiqueta" => "Fig. 7" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr7.jpeg" "Alto" => 2346 "Ancho" => 3252 "Tamanyo" => 620104 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">FDG-PET and amyloid (florbetapir) in progressive primary logopenic aphasia. The number of amyloid-positive cases was high, thereby confirming its relationship with Alzheimer disease. These amyloid-positive subjects present a temporoparietal metabolic phenotype (FDG). The amyloid-negative group showed more extensive hypometabolism extending to the anterior temporal and frontal basal region and may correspond to frontotemporal degeneration (by Cabrera et al.; H. Clínico San Carlos).</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Serena Puig" "autores" => array:1 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Serena Puig" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X1500092X" "doi" => "10.1016/j.remn.2015.07.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X1500092X?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000944?idApp=UINPBA00004N" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000944/v1_201510310036/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S2253808915000920" "issn" => "22538089" "doi" => "10.1016/j.remnie.2015.09.001" "estado" => "S300" "fechaPublicacion" => "2015-11-01" "aid" => "690" "copyright" => "Elsevier España, S.L.U. and SEMNIM" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Rev Esp Med Nucl Imagen Mol. 2015;34:396-7" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:2 [ "total" => 57 "formatos" => array:2 [ "HTML" => 34 "PDF" => 23 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Interesting images</span>" "titulo" => "<span class="elsevierStyleSup">18</span>F-FDG PET/CT in a bilateral lacrimal gland infiltration of mantle cell lymphoma" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "396" "paginaFinal" => "397" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "<span class="elsevierStyleSup">18</span>F-FDG PET/TC en un caso de infiltración lacrimal bilateral por linfoma de células del manto" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1887 "Ancho" => 3000 "Tamanyo" => 639144 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">T1 Spin-Echo sequences with selective fat suppression (SPIR) in the MRI before gadolinium i.v. injection (A), <span class="elsevierStyleSup">18</span>F-FDG PET/CT images (B, C and D) and Hematoxylin–Eosin staining (E). Images showed bilateral intraorbital lesions (A) which evidenced bilateral increased uptake of <span class="elsevierStyleSup">18</span>F-FDG in lacrimal glands (B), as well as supradiaphragmatic FDG-avid adenopathies (C and D). These findings are consistent with malignancy. Hematoxylin–Eosin staining of lacrimal gland (E) showed diffuse lymphomatous infiltration.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "A. Martínez-Esteve, F.J. García-Gómez, J.J. Borrero-Martin, E. Fajardo-Pico, I. Borrego-Dorado" "autores" => array:5 [ 0 => array:2 [ "nombre" => "A." "apellidos" => "Martínez-Esteve" ] 1 => array:2 [ "nombre" => "F.J." "apellidos" => "García-Gómez" ] 2 => array:2 [ "nombre" => "J.J." "apellidos" => "Borrero-Martin" ] 3 => array:2 [ "nombre" => "E." "apellidos" => "Fajardo-Pico" ] 4 => array:2 [ "nombre" => "I." "apellidos" => "Borrego-Dorado" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S2253654X15000335" "doi" => "10.1016/j.remn.2015.03.006" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => false "ES2" => false "LATM" => false ] "gratuito" => false "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253654X15000335?idApp=UINPBA00004N" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000920?idApp=UINPBA00004N" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000920/v1_201510310036/en/main.assets" ] "en" => array:16 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Interesting image</span>" "titulo" => "Diagnosis of recurrent glioma and antiangiogenic treatment response by <span class="elsevierStyleSup">11</span>C-Methionine PET" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "398" "paginaFinal" => "399" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J.R. García, M. Baquero, P. Bassa, M. Soler, M. Moragas, E. Riera" "autores" => array:6 [ 0 => array:4 [ "nombre" => "J.R." "apellidos" => "García" "email" => array:1 [ 0 => "jrgarcia@cetir.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:2 [ "nombre" => "M." "apellidos" => "Baquero" ] 2 => array:2 [ "nombre" => "P." "apellidos" => "Bassa" ] 3 => array:2 [ "nombre" => "M." "apellidos" => "Soler" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Moragas" ] 5 => array:2 [ "nombre" => "E." "apellidos" => "Riera" ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad PET, CETIR-ERESA, Esplugues, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con <span class="elsevierStyleSup">11</span>C-metionina" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 3250 "Tamanyo" => 518779 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Imaging study after Stupp treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with <span class="elsevierStyleSup">11</span>C-Methionine. MR shows a rounded lesion located at the genu of corpus callosum measuring 22<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>18, with adjacent bilateral frontal angiogenic edema, consistent with local recurrence. PET with <span class="elsevierStyleSup">11</span>C-Methionine shows hypermetabolic lesion (SUV target/background ratio is 5.6/1.6), thus confirming tumor recurrence. Quantification was achieved through relationship between uptake avidity of the lesion (SUV maximum) and background of gray substance of the healthy contralateral lobe (SUV mean). (B) Imaging study after Bevacizumab treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with <span class="elsevierStyleSup">11</span>C-Methionine. MR shows an increase of size at the lesion located at the genu of corpus callosum (27<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>24), with similar perilesional edema spread. The PET study with <span class="elsevierStyleSup">11</span>C-Methionine shows normalization of previous metabolic activity in lesion, thus confirming response to antiangiogenic treatment, and therapy was carried on with no further suspicious signs of recurrence in our patient.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">A 60-year-old woman with history of multifocal glioblastoma surgically resected and treated with chemotherapy and radiotherapy, presented MR findings suspected of tumor recurrence. A PET with <span class="elsevierStyleSup">11</span>C-Methionine was performed, which showed high metabolic activity within the MR lesion, thus confirming a tumor recurrence (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>A).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">Nowadays, it is widely accepted that the first therapeutic modality of glioma requires tumor resection as extensive as possible, followed by radiotherapy with neo-adjuvant, concomitant and adjuvant chemotherapy (Temozolomide-Temodal; Stupp protocol), with survival rates ranging from 10% to 40% by 2 years.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">1</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">At present, there are also second-line treatments available for recurrent gliomas, including antiangiogenic therapies and targeted therapy based on genomic differentiation (methylated O-6-methylguanine-DNA methyltransferase gene promoter MGMT, epidermal growth factor receptor EGFR, IDH1 gene, 1p/19q deletion).</p><p id="par0020" class="elsevierStylePara elsevierViewall">A high amount of vascular epithelial growth factor-A (VEGF-A) is found in gliomas, due to their high proliferation rate. In 2009, the Food and Drug Administration approved the use of Bevacizumab (Avastin), a monoclonal antibody against the vascular endothelial growth factor, for the treatment of recurrent glioblastoma.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">2</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">In our case, the MR study performed for monitoring of Bevacizumab therapy showed persistence of lesion, and even increasing size. Since tumor progression was suspected, a subsequent PET study with <span class="elsevierStyleSup">11</span>C-Methionine was repeated, which showed normalization of previous metabolic activity seen in lesion, thus confirming good response to antiangiogenic therapy (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>B).</p><p id="par0030" class="elsevierStylePara elsevierViewall">Multiparametric MR is the first-line technique for the diagnosis of gliomas, as well as for post-treatment evaluation: early study after surgery and sequentially after chemo/radiotherapy. However, MR changes do not allow differentiating between radionecrosis and tumor recurrence in many cases. Changes in brain–blood barrier status secondary to antiangiogenic therapy may result in false-progression MR images (pseudo-progression).<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">3</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">PET with <span class="elsevierStyleSup">11</span>C-Methionine is indicated to differentiate between tumor recurrence, which is shown by high tracer uptake, and radionecrosis, shown by absent metabolic activity. <span class="elsevierStyleSup">11</span>C-Metionine uptake in malignancy is dependent on the increase in transport and metabolism of aminoacids in tumor tissue, independently of the disruption of the blood–brain barrier, thus with a potential usefulness for the evaluation of response to antiangiogenic therapies.<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">3</span></a></p><p id="par0040" class="elsevierStylePara elsevierViewall">This case illustrates the usefulness of PET with <span class="elsevierStyleSup">11</span>C-Metionine for the detection of recurrent glioma, as well as its usefulness for the evaluation of treatment response to new second-line agents.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2015-03-06" "fechaAceptado" => "2015-04-15" "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: García JR, Baquero M, Bassa P, Soler M, Moragas M, Riera E. Diagnóstico de recurrencia de un glioma y respuesta al tratamiento antiangiogénico mediante PET con 11C-metionina. Rev Esp Med Nucl Imagen Mol. 2015. <span class="elsevierStyleInterRef" id="intr0005" href="doi:10.1016/j.remn.2015.04.001">http://dx.doi.org/10.1016/j.remn.2015.04.001</span></p>" ] ] "multimedia" => array:1 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2375 "Ancho" => 3250 "Tamanyo" => 518779 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">(A) Imaging study after Stupp treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with <span class="elsevierStyleSup">11</span>C-Methionine. MR shows a rounded lesion located at the genu of corpus callosum measuring 22<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>18, with adjacent bilateral frontal angiogenic edema, consistent with local recurrence. PET with <span class="elsevierStyleSup">11</span>C-Methionine shows hypermetabolic lesion (SUV target/background ratio is 5.6/1.6), thus confirming tumor recurrence. Quantification was achieved through relationship between uptake avidity of the lesion (SUV maximum) and background of gray substance of the healthy contralateral lobe (SUV mean). (B) Imaging study after Bevacizumab treatment: T1-weighted and Flair sequences MR imaging. PET/MR imaging fusion by means of software (SPM8). PET imaging with <span class="elsevierStyleSup">11</span>C-Methionine. MR shows an increase of size at the lesion located at the genu of corpus callosum (27<span class="elsevierStyleHsp" style=""></span>×<span class="elsevierStyleHsp" style=""></span>24), with similar perilesional edema spread. The PET study with <span class="elsevierStyleSup">11</span>C-Methionine shows normalization of previous metabolic activity in lesion, thus confirming response to antiangiogenic treatment, and therapy was carried on with no further suspicious signs of recurrence in our patient.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:3 [ 0 => array:3 [ "identificador" => "bib0020" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemoradiotherapy in malignant glioma: standard of care and future directions" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "R. Stupp" 1 => "M.E. Hegi" 2 => "M.R. Gilbert" 3 => "A. Chakravarti" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2007" "volumen" => "10" "paginaInicial" => "4127" "paginaFinal" => "4136" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0025" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Bevacizumab and recurrent malignant gliomas: a European perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "W. Wick" 1 => "M. Weller" 2 => "M. van den Bent" 3 => "R. Stupp" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Clin Oncol" "fecha" => "2010" "volumen" => "20" "paginaInicial" => "e188" "paginaFinal" => "e189" ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0030" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Neuroimaging in brain tumors" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Arbizu" 1 => "P.D. Domínguez" 2 => "R. Diez-Valle" 3 => "C. Vigil" 4 => "R. García-Eulate" 5 => "J.L. Zubieta" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.remn.2010.11.001" "Revista" => array:6 [ "tituloSerie" => "Rev Esp Med Nucl" "fecha" => "2011" "volumen" => "30" "paginaInicial" => "47" "paginaFinal" => "65" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21211868" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/22538089/0000003400000006/v1_201510310036/S2253808915000932/v1_201510310036/en/main.assets" "Apartado" => array:4 [ "identificador" => "7927" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Interesting images" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/22538089/0000003400000006/v1_201510310036/S2253808915000932/v1_201510310036/en/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2253808915000932?idApp=UINPBA00004N" ]
Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación
Esté informado en todo momento gracias a las alertas y novedades
Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados
The Revista Española de Medicina Nuclear e Imagen Molecular (Spanish Journal of Nuclear Medicine and Molecular Imaging), was founded in 1982, and is the official journal of the Spanish Society of Nuclear Medicine and Molecular Imaging, which has more than 700 members. The Journal, which publishes 6 regular issues per year, has the promotion of research and continuing education in all fields of Nuclear Medicine as its main aim. For this, its principal sections are Originals, Clinical Notes, Images of Interest, and Special Collaboration articles. The works may be submitted in Spanish or English and are subjected to a peer review process. In 2009, it became the leading Spanish journal in the field of Medical Imaging on having an Impact Factor , awarded by the Journal Citation Reports.
Science Citation Index Expander, Medline, IME, Bibliomed, EMBASE/Excerpta Medica, Healthstar, Cancerlit, Toxine, Inside Conferences, Scopus
See moreThe Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.
© Clarivate Analytics, Journal Citation Reports 2022
SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.
See moreSNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.
See moreRevista Española de Medicina Nuclear e Imagen Molecular (English Edition)
¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?
Are you a health professional able to prescribe or dispense drugs?
Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos